Plunkett Research Online: Intellia Therapeutics

INTELLIA THERAPEUTICS (NTLA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Intellia Therapeutics Inc was incorporated in Delaware in May 2014, as AZRN, Inc. In July 2014, the Company changed its name from AZRN, Inc to Interllia Therapeutics Inc. It is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological .....



Intellia Therapeutics
Ticker: NTLA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 857 285-6200
Fax:
Address: 40 Erie Street
Suite 130
Cambridge, MA 02139 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing
ContactsDescription
John LeonardCEO/Director/President
Glenn GoddardCFO/Chief Accounting Officer/Executive VP
See More
Intellia Therapeutics Inc was incorporated in Delaware in May 2014, as AZRN, Inc. In July 2014, the Company changed its name from AZRN, Inc to Interllia Therapeutics Inc. It is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological .....See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201820182017201720172017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: